Rising regulatory demands and the growing complexity of medical technology are driving steady expansion in the global medical device testing market, which was valued at USD 11.44 billion in 2023 and is projected to reach USD 17.71 billion by 2031, growing at a compound annual growth rate of 5.68%. As chronic disease prevalence climbs worldwide and health authorities tighten safety requirements, manufacturers are being compelled to invest more heavily in comprehensive evaluation processes before bringing new devices to market.

Medical device testing encompasses the full range of evaluations — including performance testing, biocompatibility assessment, mechanical integrity checks, and sterilization validation — required to confirm that a device is safe, functional, and compliant with standards set by regulatory bodies such as the FDA and EMA. As devices grow increasingly sophisticated, particularly with the integration of IoT connectivity and personalized medicine applications, rigorous testing has become essential to preventing malfunctions and ensuring long-term product reliability.

Chronic Disease Burden Reinforces Long-Term Demand

A central driver of market growth is the rising global prevalence of chronic conditions such as diabetes and cardiovascular disease. The Institute for Health Metrics and Evaluation reports that more than half a billion people worldwide currently live with diabetes, a figure projected to exceed 1.3 billion within three decades, with North Africa and the Middle East facing the steepest anticipated increases. This mounting disease burden is placing sustained pressure on healthcare systems to deploy reliable, high-quality diagnostic and treatment devices — a dynamic that continues to reinforce demand for thorough testing and certification services across the industry.

Regulatory Pressure Drives Investment in Compliance

Stricter oversight from health authorities is compelling manufacturers to embed rigorous testing at every stage of the product lifecycle, from initial development through post-market surveillance. Non-compliance carries steep consequences, including costly delays and product recalls, giving companies strong incentive to invest proactively in comprehensive testing infrastructure. In April 2023, Nelson Labs received ASCA accreditation from the FDA as a biocompatibility testing laboratory, reflecting the kind of specialized credentialing increasingly required to serve manufacturers navigating complex regulatory pathways.

High compliance costs remain a genuine constraint, particularly as evolving standards demand continual investment in advanced testing methods. In response, industry players are increasingly turning to automation and digital technologies to streamline testing processes, while forming strategic partnerships that consolidate multiple testing capabilities under single, integrated service offerings. A March 2023 collaboration between Nemera and Nelson Labs Europe, for example, brought together leachables, extractables, microbiology, biocompatibility, and chemical testing under one coordinated service framework.

AI Integration and Patient-Centric Testing Gain Momentum

The adoption of artificial intelligence and machine learning is significantly enhancing testing efficiency and accuracy across the industry. These technologies enable more precise predictive modeling of device performance and failure risk, reducing both testing time and the potential for human error. Reflecting this shift, Eurofins BioPharma Product Testing partnered with Huma in August 2023 to develop digital clinical trial solutions specifically for medical devices, aiming to accelerate manufacturers’ path to market.

Simultaneously, the industry is moving toward more patient-centric testing approaches, with manufacturers increasingly incorporating real-world patient feedback into the evaluation process. This shift is helping companies design more intuitive, effective devices while reducing failure rates tied to poor usability — a trend expected to shape product development strategy well beyond the current forecast period.

Testing Services and Class II Devices Lead Segmentation

By service, testing represented the largest segment in 2023, generating USD 5.44 billion in revenue, driven by mounting regulatory requirements and the rising prevalence of chronic disease. A 2022 partnership between Eurofins and SGS to jointly expand testing service offerings illustrates the kind of consolidation occurring as providers seek to meet growing global demand.

By device class, Class II devices — including infusion pumps, surgical drapes, and diagnostic imaging equipment — captured the largest share at 50.44% in 2023, propelled by rising chronic disease treatment needs and expanding remote monitoring capabilities. By technology, in vitro diagnostic devices are projected to generate the highest revenue by 2031, at USD 4.86 billion, as demand grows for early disease detection and point-of-care testing accessibility.

North America Leads, Asia-Pacific Set for Fastest Growth

North America held the largest regional share in 2023, at 46.50% of global revenue, worth USD 5.32 billion, supported by high healthcare expenditure and a concentration of leading device manufacturers and research institutions. Strict FDA oversight continues to reinforce demand for comprehensive testing, while a growing trend toward outsourced testing services is allowing manufacturers to focus resources on core product development.

Asia-Pacific is expected to be the fastest-growing region, expanding at a CAGR of 7.34% to reach a projected USD 3.72 billion by 2031. Regional initiatives are accelerating this trajectory, including the 2023 launch of new testing and prototyping devices in India’s Telangana state, and Tata Consultancy Services’ introduction of a streamlined single-window portal for importing medical devices — a move designed to simplify regulatory processes and accelerate market access across the region.

Competitive Landscape

Key players shaping the market include SGS Société Générale de Surveillance, Laboratory Corporation of America Holdings, Nelson Laboratories, TÜV SÜD, Charles River Laboratories, Eurofins Scientific, Pace Analytical Services, Intertek Group, and WuXi AppTec, with competition centered on laboratory expansion, R&D investment, and strategic partnerships. Notable recent developments include Stryker’s 2024 opening of a dedicated life-cycle testing facility in India and TidalSense’s launch of a pilot study for a pediatric asthma diagnostic device.

Outlook

With chronic disease prevalence continuing to climb and regulatory frameworks growing more stringent worldwide, the medical device testing market is positioned for durable, mid-single-digit growth through 2031. Industry stakeholders anticipate that AI-enabled testing methodologies and expanding outsourcing partnerships will play an increasingly central role in helping manufacturers balance compliance demands with faster time-to-market.